Ying Du Sells 2,945 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du sold 2,945 shares of Zai Lab stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $33.11, for a total transaction of $97,508.95. Following the completion of the sale, the chief executive officer now directly owns 479,851 shares in the company, valued at approximately $15,887,866.61. This represents a 0.61 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Ying Du also recently made the following trade(s):

• On Wednesday, April 2nd, Ying Du sold 5,808 shares of Zai Lab stock. The stock was sold at an average price of $35.89, for a total transaction of $208,449.12.
• On Monday, March 3rd, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $32.44, for a total transaction of $1,622,000.00.
• On Friday, February 28th, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $34.47, for a total transaction of $1,723,500.00.

Zai Lab Price Performance

Shares of Zai Lab stock opened at $27.06 on Thursday. Zai Lab Limited has a 1 year low of $13.48 and a 1 year high of $39.77. The firm has a market cap of $2.97 billion, a PE ratio of -9.77 and a beta of 1.09. The company has a 50 day simple moving average of $32.74 and a two-hundred day simple moving average of $28.99.

Zai Lab (NASDAQ:ZLAB) last announced its earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.19). Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The company had revenue of $109.07 million for the quarter, compared to the consensus estimate of $110.15 million. As a group, research analysts anticipate that Zai Lab Limited will post -2.58 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ZLAB shares. Scotiabank started coverage on shares of Zai Lab in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 target price for the company. Bank of America reiterated a “neutral” rating and issued a $36.10 target price (up previously from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd. JPMorgan Chase & Co. boosted their price objective on shares of Zai Lab from $44.00 to $51.00 and gave the company an “overweight” rating in a research note on Thursday, March 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research note on Thursday, March 27th.

Institutional Investors Weigh In On Zai Lab

Hedge funds have recently bought and sold shares of the stock. Point72 Asset Management L.P. bought a new stake in shares of Zai Lab in the 3rd quarter worth approximately $325,000. Wellington Management Group LLP lifted its holdings in shares of Zai Lab by 18.4% in the 3rd quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company’s stock worth $203,660,000 after acquiring an additional 1,312,115 shares during the last quarter. XTX Topco Ltd lifted its holdings in shares of Zai Lab by 8.0% in the 3rd quarter. XTX Topco Ltd now owns 31,618 shares of the company’s stock worth $763,000 after acquiring an additional 2,335 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of Zai Lab in the 3rd quarter worth approximately $225,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Zai Lab in the 3rd quarter worth approximately $369,000. 41.65% of the stock is currently owned by institutional investors.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.